Update on apomorphine for the rapid treatment of hypomobility ("off") episodes in Parkinson's disease

Pharmacotherapy

Volumn 26, Issue 6 I, 2006, Pages 840-852

  Obering, Crystal D ^a   Chen, Jack J ^b   Swope, David M ^b  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b LOMA LINDA UNIVERSITY   (United States)

Author keywords

Apomorphine; Dose failure; Hypomobility; Levodopa; Mobility; Motor fluctuations; Parkinson's disease

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCHOLINE; AMANTADINE; APOMORPHINE; BENSERAZIDE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; GLUTAMIC ACID; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

AKINESIA; CLINICAL TRIAL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG TOLERABILITY; HUMAN; HYPOMOBILITY; NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PATIENT MOBILITY; QUALITY OF LIFE; REVIEW;

ANTIPARKINSON AGENTS; APOMORPHINE; DOPAMINE; DYSKINESIA, DRUG-INDUCED; HUMANS; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; PARKINSON DISEASE;

EID: 33744465789     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.6.840     Document Type: Review

References (68)

1. Parkinson J. An essay on the shaking palsy. London, England: Sherwood, Neely and Jones, 1817.
2. Samii A, Nutt JG, Ransom BR. Parkinson's disease. Lancet 2004;363:1783-93.
3. Olanow CW, Perl DP, DeMartino GN, McNaught KS. Lewy-body formation is an aggresome-related process: a hypothesis. Lancet Neurol 2004;3:496-503.
4. Swerdlow RH, Parks JK, Miller SW, et al. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann Neurol 1996;40:663-71.
5. Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 2003;53(suppl 3):S26-38.
6. Smeltzer SC, Bare BG, eds. Brunner and Suddarth's textbook of medical-surgical nursing. Philadelphia, PA: Lippincott, Williams & Wilkins, 2000.
7. Quinn N. Classification of fluctuations in patients with Parkinson's disease. Neurology 1998;51(2 suppl 2):S25-9.
8. Poewe W. Clinical aspects of motor fluctuations in Parkinson's disease. Neurology 1994;44(7 suppl 6):S6-9.
9. Pahwa R, Lyons KE. Options in the treatment of motor fluctuations and dyskinesias in Parkinson's disease: a brief review. Neurol Clin 2004;22(3 suppl):S35-52.
10. Swope DM. Rapid treatment of "wearing off" in Parkinson's disease. Neurology 2004;62(suppl 4):S27-31.
11. Jankovic J. Complications and limitations of drug therapy for Parkinson's disease. Neurology 2000;55(12 suppl 6):S2-6.
12. Koller WC. Management of motor fluctuations in Parkinson's disease. Eur Neurol 1996;36(suppl 1):43-8.
13. Olanow CW, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines. Neurology 1998;50(3 suppl 3):S1-57.
14. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001;56(11 suppl 5):S1-88.
15. Contin M, Riva R, Martinelli P, Cortelli P, Albani F, Baruzzi A. Concentration-effect relationship of levodopa-benserazide dispersible formulation versus standard form in the treatment of complicated motor response fluctuations in Parkinson's disease. Clin Neuropharmacol 1999;22:351-5.
16. Kurth MC. Using liquid levodopa in the treatment of Parkinson's disease: a practical guide. Drugs Aging 1997;10:332-40.
17. Martinez-Martin P, O'Brien CF. Extending levodopa action: COMT inhibition. Neurology 1998;50(suppl 6):S27-32.
18. Anonymous. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 1997;42:747-55.
19. Djaldetti R, Atlas D, Melamed E. Effect of subcutaneous administration of levodopa ethyl ester, a soluble prodrug of levodopa, on dopamine metabolism in rodent striatum: implication for treatment of Parkinson's disease. Clin Neuropharmacol 1996;19:65-71.
20. Stocchi F, Barbato L, Bramante L, Bonamartini A, Ruggieri S. The clinical efficacy of a single afternoon dose of levodopa methyl ester: a double-blind cross-over study versus placebo. Funct Neurol 1994;9:259-64.
21. Stocchi F, Barbato L, Bramante L, Nordera G, Vacca L, Ruggieri S. Fluctuating parkinsonism: a pilot study of single afternoon dose of levodopa methyl ester. J Neurol 1996;243:377-80.
22. Kao HD, Traboulsi A, Itoh S, Dittert L, Hussain A. Enhancement of the systemic and CNS specific delivery of L-dopa by the nasal administration of its water soluble prodrugs. Pharm Res 2000;17:978-84.
23. Sudo J, Iwase H, Higashiyama K, et al. Elevation of plasma levels of L-dopa in transdermal administration of L-dopa-butylester in rats. Drug Dev Ind Pharm 2002;28:59-65.
24. 24; Bracco F, Malesani R, Saladini M, Battistin L. Protein redistribution diet and antiparkinsonian response to levodopa. Eur Neurol 1991;31:68-71.
25. Robertson DR, Higginson I, Macklin BS, Renwick AG, Waller DG, George CF. The influence of protein containing meals on the pharmacokinetics of levodopa in healthy volunteers. Br J Clin Pharmacol 1991;31:413-17.
26. Brannan T, Martinez-Tica J, Yahr MD. Effect of dietary protein on striatal dopamine formation following L-dopa administration: an in vivo study. Neuropharmacology 1991;30:1125-7.
27. Cedarbaum JM, Kutt H, McDowell FH. A pharmacokinetic and pharmacodynamic comparison of Sinemet CR (50/200) and standard Sinemet (25/100). Neurology 1989;39(11 suppl 2):38-44.
28. LeWitt PA, Nelson MV, Berchou RC, et al. Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies. Neurology 1989;39(11 suppl 2):45-53.
29. Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet 2002;41:261-309.
30. Contin M, Riva R, Martinelli P, Cortelli P, Albani F, Baruzzi A. Longitudinal monitoring of the levodopa concentration-effect relationship in Parkinson's disease. Neurology 1994;44:1287-92.
31. Kaakkola S. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs 2000;59:1233-50.
32. Nutt JG, Woodward WR, Beckner RM, et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 1994;44:913-19.
33. Jorga KM. Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: a review of early studies in volunteers. Neurology 1998;50(5 suppl 5):S31-8.
34. Piccini P, Brooks DJ, Korpela K, Pavese N, Karlsson M, Gordin A. The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease. J Neurol Neurosurg Psychiatry 2000;68:589-94.
35. Metman LV, Hoff J, Mouradian MM, Chase TN. Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa. Mov Disord 1994;9:463-5.
36. Pappen EJ, Goetz CG, Niederman F, Ling ZD, Stebbins GT, Carvey PM. Liquid levodopa/carbidopa produces significant improvement in motor function without dyskinesia exacerbation. Neurology 1996;47:1493-5.
37. Contin M, Riva R, Martinelli P, Cortelli P, Albani F, Baruzzi A. Concentration-effect relationship of levodopa-benserazide dispersible formulation versus standard form in the treatment of complicated motor response fluctuations in Parkinson's disease. Clin Neuropharmacol 1999;22:351-5.
38. Nahata MC, Morosco RS, Leguire LE. Development of two stable oral suspensions of levodopa-carbidopa for children with amblyopia. J Pediatr Ophthalmol Strabismus 2000;37:333-7.
39. Kurth MC, Tetrud JW, Irwin I, Lyness WH, Langston JW. Oral levodopa/carbidopa solution versus tablets in Parkinson's patients with severe fluctuations: a pilot study. Neurology 1993;43:1036-9.
40. Goetz CG, Koller WC, Poewe W, et al. DA agonist-non-ergot derivatives: apomorphine. Mov Disord 2002;17(suppl 4):S83-9.
41. Van der Geest R, van Laar T, Kruger PP, et al. Pharmacokinetics, enantiomer interconversion and metabolism of R-apomorphine in patients with idiopathic Parkinson's disease. Clin Neuropharmacol 1998;21:159-68.
42. Neef C, van Laar T. Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease. Clin Pharmacokinet 1999;37:257-71.
43. Muguet D, Brousselle E, Chazot G. Apomorphine in patients with Parkinson's disease. Biomed Pharmacother 1995;49:197-209.
44. Stibe CM, Kempster PA, Lees AJ, Stern GM. Subcutaneous apomorphine in Parkinsonian on-off oscillations. Lancet 1988;1:403-6.
45. Kempster PA, Frankel FP, Stern GM, Lees AJ. Comparison of motor response to apomorphine and levodopa in Parkinson's disease. J Neurol Neurosurg Psychiatry 1990;53:1004-7.
46. Pollak P, Champay AS, Hommel M, Perret JE, Benabid AL. Subcutaneous apomorphine in Parkinson's disease [letter]. J Neurol Neurosurg Psychiatry 1989;52:544.
47. Poewe W, Kleedorfer B, Gerstenbrand F, Oertel W. Subcutaneous apomorphine in Parkinson's disease [letter]. Lancet 1988;1:943.
48. Poewe W, Kleedorfer B, Wagner M, Benke T, Gassser T, Oertel W. Side-effects of subcutaneous apomorphine in Parkinson's disease [letter]. Lancet 1989;1:1084-5.
49. Frankel JP, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 1990;53:96-101.
50. Hughes AJ, Lees AJ, Stern GM. The motor response to sequential apomorphine in Parkinsonian fluctuations. J Neurol Neurosurg Psychiatry 1991;54:358-60.
51. Hughes AJ, Bishop S, Stern GM, Lees AJ. The motor response to repeated apomorphine administration in Parkinson's disease. Clin Neuropharmacol 1991;14:209-13.
52. Hughes AJ, Bishop S, Kleedorfer B, et al. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. Mov Disord 1993;8:165-70.
53. Deffond D, Durif F, Tournilhac M. Apomorphine in treatment of Parkinson's disease: comparison between subcutaneous and sublingual routes. J Neurol Neurosurg Psychiatry 1993;56:101-3.
54. Gervason CL, Pollak PR, Limousin P, Perret JE. Reproducibility of motor effects induced by successive subcutaneous apomorphine injections in Parkinson's Disease. Clin Neuropharmacol 1993;2:113-19.
55. Ostergaard L, Werdelin L, Odin P, et al. Pen injected apomorphine against off phenomena in late Parkinson's disease: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1995;58:681-7.
56. Pietz K, Hagell P, Odin P. Subcutaneous apomorphine in late state Parkinson's disease: a long term follow up. J Neurol Neurosurg Psychiatry 1998;65:709-16.
57. Dewey RB, Hutton JT, LeWitt PA, Factor SA. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for Parkinsonian off-state events. Arch Neurol 2001;58:1385-92.
58. Mylan Bertek Pharmaceuticals Inc. NDA 21-264. Apokyn (apomorphine hydrochloride injection) 10 mg/mL. Durham, NC; April 2004.
59. Sherry JH, Guyton PJ, van Lunen B, Bottini PB. Continued efficacy and safety of subcutaneous injections of apomorphine in the treatment of off episodes in patients with Parkinson's disease [abstr]. Neurology 2003;60(suppl 1):A81.
60. Trosch R for the APO303 Investigators. Decrease in UPDRS motor scores following intermittent subcutaneous apomorphine for 6 months in patients with advanced Parkinson's disease [abstr]. Mov Disord 2004;19(suppl 9):S217.
61. Cotzias GC, Papavasiliou PS, Fehling C, Kaufman B, Mena I. Similarities between neurologic effects of L-dopa and of apomorphine. N Engl J Med 1970;1:31-3.
62. Merello M, Pikielny R, Cammarota A, Leiguarda R. Comparison of subcutaneous apomorphine versus dispersible Madopar latency and effect duration in Parkinson's disease patients: a double-blind single-dose study. Clin Neuropharmacol 1997;20:165-7.
63. Hardie RJ, Lees AJ, Stern GM. On-off fluctuations in Parkinson's disease. Brain 1984;107:487-506.
64. van Laar T, Jansen ENH, Essink AWG, Neef C, Oosterloo S, Roos RAC. A double-blind study of the efficacy of apomorphine and its assessment in 'off'-periods in Parkinson's disease. Clin Neurol Neurosurg 1993;95:231-5.
65. Dewey RB Jr for the APO-401 Investigators. Use of trimethobenzamide for the control of nausea in advanced Parkinson's disease patients treated with subcutaneous apomorphine [abstr]. Mov Disord 2004;19:520.
66. Dodel RC, Berger K, Oertel WH. Health-related quality of life and healthcare utilization in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias. Pharmacoeconomics 2001;19:1013-38.
67. Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease: a community-based study. Brain 2000;123:2297-305.
68. Carter JH, Stewart BJ, Archbold PG, et al. Living with a person who had Parkinson's disease: the spouse's perspective by stage of disease. Parkinson's study group. Mov Disord 1998;113:20-8.